Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics

Dimitri P Mikhailidis; Vasilios G Athyros

doi:10.1038/nrcardio.2013.209

Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics

Nat Rev Cardiol. 2014 Feb;11(2):72-4. doi: 10.1038/nrcardio.2013.209. Epub 2013 Dec 24.

Authors

Dimitri P Mikhailidis¹, Vasilios G Athyros²

Affiliations

¹ Department of Clinical Biochemistry (Vascular Prevention Clinic), Royal Free Hospital Campus, University College School of Medicine, Pond Street, London NW3 2QG, UK.
² Atherosclerosis and Metabolic Syndrome Outpatient Units, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 15 Marmara Street, 55132 Thessaloniki, Greece.

PMID: 24366071
DOI: 10.1038/nrcardio.2013.209

Abstract

The new ACC/AHA guidelines on treatment of blood cholesterol focus on intensity of statin therapy rather than target levels of lipids. Early studies show substantial reductions in LDL-cholesterol level with antibodies against PCSK9. MicroRNA silencing and gene-repair techniques to treat dyslipidaemia are promising strategies under development.

Publication types

Review

MeSH terms

Dyslipidemias / blood
Dyslipidemias / drug therapy*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Lipids / blood
Practice Guidelines as Topic*
Retrospective Studies

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids